Diego A S Toesca1, Evan C Osmundson2, Rie von Eyben1, Jenny L Shaffer1, Albert C Koong1, Daniel T Chang3. 1. Radiation Oncology Department, Stanford University School of Medicine, Stanford, California. 2. Radiation Oncology Department, Vanderbilt University School of Medicine, Nashville, Tennessee. 3. Radiation Oncology Department, Stanford University School of Medicine, Stanford, California. Electronic address: dtchang@stanford.edu.
Abstract
PURPOSE: This study aims to determine how the albumin-bilirubin (ALBI) score compares with the Child-Pugh (CP) score for assessing liver function following stereotactic body radiation therapy (SBRT). METHODS AND MATERIALS: In total, 60 patients, 40 with hepatocellular carcinoma (HCC) and 20 with cholangiocarcinoma (CCA), were treated with SBRT. Liver function panels were obtained before and at 1, 3, 6, and 12 months after SBRT. Laboratory values were censored after locoregional recurrence, further liver-directed therapies, or liver transplant. RESULTS: A significant decline in hepatic function occurred after SBRT for HCC patients only (P = .001 by ALBI score; P < .0001 by CP score). By converting radiation doses to biologically equivalent doses by using a standard linear quadratic model using α/β of 10, the strongest dosimetric predictor of liver function decline for HCC was the volume of normal liver irradiated by a dose of 40 Gy when assessing liver function by the ALBI score (P = .07), and the volume of normal liver irradiated by a dose of 20 Gy by using the CP score (P= .0009). For CCA patients, the volume of normal liver irradiated by a dose of 40 Gy remained the strongest dosimetric predictor when using the ALBI score (P = .002), but no dosimetric predictor was significant using the CP score. Hepatic function decline correlated with worse overall survival for HCC (by ALBI, P = .0005; by CP, P < .0001) and for CCA (by ALBI, P = NS; by CP, P = .008). CONCLUSIONS: ALBI score was similarly able to predict hepatic function decline compared with CP score, and both systems correlated with survival.
PURPOSE: This study aims to determine how the albumin-bilirubin (ALBI) score compares with the Child-Pugh (CP) score for assessing liver function following stereotactic body radiation therapy (SBRT). METHODS AND MATERIALS: In total, 60 patients, 40 with hepatocellular carcinoma (HCC) and 20 with cholangiocarcinoma (CCA), were treated with SBRT. Liver function panels were obtained before and at 1, 3, 6, and 12 months after SBRT. Laboratory values were censored after locoregional recurrence, further liver-directed therapies, or liver transplant. RESULTS: A significant decline in hepatic function occurred after SBRT for HCC patients only (P = .001 by ALBI score; P < .0001 by CP score). By converting radiation doses to biologically equivalent doses by using a standard linear quadratic model using α/β of 10, the strongest dosimetric predictor of liver function decline for HCC was the volume of normal liver irradiated by a dose of 40 Gy when assessing liver function by the ALBI score (P = .07), and the volume of normal liver irradiated by a dose of 20 Gy by using the CP score (P= .0009). For CCA patients, the volume of normal liver irradiated by a dose of 40 Gy remained the strongest dosimetric predictor when using the ALBI score (P = .002), but no dosimetric predictor was significant using the CP score. Hepatic function decline correlated with worse overall survival for HCC (by ALBI, P = .0005; by CP, P < .0001) and for CCA (by ALBI, P = NS; by CP, P = .008). CONCLUSIONS:ALBI score was similarly able to predict hepatic function decline compared with CP score, and both systems correlated with survival.
Authors: Judit Boda-Heggemann; Anika Jahnke; Mark K H Chan; Leila S Ghaderi Ardekani; Peter Hunold; Jost Philipp Schäfer; Stefan Huttenlocher; Stefan Wurster; Dirk Rades; Guido Hildebrandt; Frank Lohr; Jürgen Dunst; Frederik Wenz; Oliver Blanck Journal: Strahlenther Onkol Date: 2018-02-05 Impact factor: 3.621
Authors: Kimberly L Shampain; Caitlin E Hackett; Sohrab Towfighi; Anum Aslam; William R Masch; Alison C Harris; Silvia D Chang; Kanika Khanna; Vivek Mendiratta; Ahmed M Gabr; Dawn Owen; Mishal Mendiratta-Lala Journal: Abdom Radiol (NY) Date: 2021-05-07
Authors: W C Jackson; K Suresh; C Maurino; M Feng; K C Cuneo; R K Ten Haken; T S Lawrence; M J Schipper; D Owen Journal: Radiother Oncol Date: 2019-08-17 Impact factor: 6.280
Authors: Krithika Suresh; Dawn Owen; Latifa Bazzi; William Jackson; Randall K Ten Haken; Kyle Cuneo; Mary Feng; Theodore S Lawrence; Matthew J Schipper Journal: Int J Radiat Oncol Biol Phys Date: 2017-09-22 Impact factor: 7.038
Authors: William C Jackson; Holly E Hartman; Laila A Gharzai; Christopher Maurino; David M Karnak; Mishal Mendiratta-Lala; Neehar D Parikh; Charles S Mayo; Randall K Ten Haken; Matthew J Schipper; Kyle C Cuneo; Theodore S Lawrence Journal: Int J Radiat Oncol Biol Phys Date: 2021-04-18 Impact factor: 8.013
Authors: Diego A S Toesca; Bulat Ibragimov; Amanda J Koong; Lei Xing; Albert C Koong; Daniel T Chang Journal: J Radiat Res Date: 2018-03-01 Impact factor: 2.724
Authors: Stephanie K Schaub; Pehr E Hartvigson; Michael I Lock; Morten Høyer; Thomas B Brunner; Higinia R Cardenes; Laura A Dawson; Edward Y Kim; Nina A Mayr; Simon S Lo; Smith Apisarnthanarax Journal: Technol Cancer Res Treat Date: 2018-01-01